Biodesix has reported that its pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (sutent) and erlotinib (tarceva), by survival outcomes.
VeriStrat, a serum proteomic test for patients with advanced non-small cell lung cancer (NSCLC), identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).
The retrospective fully blinded study applied the VeriStrat test to a subset of the patient population from a Phase I/II clinical trial of erlotinib plus sunitinib in RCC patients.
Serum samples from patients are processed in Biodesix’ CLIA accredited laboratory and results are reported within 72 hours.
Results showed that VeriStrat Good patients had longer progression free survival (PFS) and overall survival (OS) when treated with the combination therapy as compared to patients who tested VeriStrat Poor.
Biodesix chief technology officer Heinrich Roder said the data showed VeriStrat may be helpful in identifying specific and useful disease characteristics in RCC.
”We are continuously engaging in additional studies to further explore the full clinical utility of VeriStrat,” Roder added.
